Last reviewed · How we verify
Staphylococcal investigational vaccine GSK2392103A
Staphylococcal investigational vaccine GSK2392103A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | Staphylococcal investigational vaccine GSK2392103A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Staphylococcal investigational vaccine GSK2392103A CI brief — competitive landscape report
- Staphylococcal investigational vaccine GSK2392103A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Staphylococcal investigational vaccine GSK2392103A
What is Staphylococcal investigational vaccine GSK2392103A?
Staphylococcal investigational vaccine GSK2392103A is a Biologic drug developed by GlaxoSmithKline.
Who makes Staphylococcal investigational vaccine GSK2392103A?
Staphylococcal investigational vaccine GSK2392103A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Staphylococcal investigational vaccine GSK2392103A in?
Staphylococcal investigational vaccine GSK2392103A is in Phase 1.